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Abstract: The absence of fluorine from most biomolecules
renders it an excellent probe for NMR spectroscopy to monitor
inhibitor–protein interactions. However, predicting the binding
mode of a fluorinated ligand from a chemical shift (or vice
versa) has been challenging due to the high electron density of
the fluorine atom. Nonetheless, reliable 19F chemical-shift
predictions to deduce ligand-binding modes hold great poten-
tial for in silico drug design. Herein, we present a systematic
QM/MM study to predict the 19F NMR chemical shifts of
a covalently bound fluorinated inhibitor to the essential
oxidoreductase tryparedoxin (Tpx) from African trypano-
somes, the causative agent of African sleeping sickness. We
include many protein–inhibitor conformations as well as
monomeric and dimeric inhibitor–protein complexes, thus
rendering it the largest computational study on chemical shifts
of 19F nuclei in a biological context to date. Our predicted shifts
agree well with those obtained experimentally and pave the way
for future work in this area.
Fluorine is considered a “magic” element in medicinal and
agricultural chemistry. It forms strong bonds to carbon, is the
smallest biocompatible hydrogen substitute,[1] has the ability
to form hydrogen bonds, and possesses a high electronega-
tivity. Its introduction into small molecules can increase
metabolic stability and allows the fine-tuning of physico-
chemical properties.[2] It is therefore not surprising that more
than 20 % of all FDA-approved drugs and more than 30% of
all agrochemicals contain fluorine.[2] Replacing hydrogen by
fluorine has been used successfully to, for example, inves-
tigate the interaction of inhibitors with proteases, explore
their active site properties, and characterize inhibitors for
neglected tropical diseases.[3]
With its 100 % natural abundance, high gyromagnetic
ratio, and the resulting high sensitivity, the spin-1/2 nucleus
19F is of particular interest for NMR studies.[4] While practical
advantages of fluorine for NMR spectroscopy have been
exploited for many decades, the performance of correspond-
ing quantum-chemical calculations for complex systems has
gained momentum only lately.[5]
Chemical shifts of compounds containing fluorine have
been calculated for many decades, from small molecules in
the gas phase over biological systems in solution to solid-
states.[6] The two most recent studies focusing on 19F chemical
shifts of biologically relevant molecules investigated crystals
of fluorinated tryptophans[7] or monofluorinated phenylala-
nines in a protein (Brd4).[8] In the case of the tryptophan
crystals, four molecules were used as a representation of the
entire crystal. For Brd4, a quantum-mechanical/molecular-
mechanical (QM/MM) setup was used with a buffer region of
4  and Boltzmann weighting of a few conformers. Nonethe-
less, the calculations differed from the measurements by
between one and more than 20 ppm even after improving
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predictions by linear regression to experimental data.
Another study benchmarked different levels of quantum-
chemical methods for fluorinated amino acids in implicit
solvent, achieving at best a mean absolute error of 2.68 ppm
with respect to the experiment.[9] Despite the impressive
progress in the field, this is not sufficient to explain subtle
differences in experimental spectra. Here, we use hundreds of
frames from molecular dynamics (MD) simulations to ensure
proper sampling of conformers and a significantly larger
buffer region in our QM/MM calculations to increase the
accuracy of our results.
Methods for computing NMR parameters range from
empirical programs, such as SPARTA + ,[10] to highly accurate
QM calculations.[5, 11, 12] When using quantum-chemical meth-
ods, it has been shown that sufficiently large QM regions are
necessary when describing complex systems.[13, 14] However,
the inclusion of many atoms is computationally very demand-
ing. Thus, a plethora of methods has been devised to reduce
the computational effort.[14,15] Here, we employ rigorous
linear-scaling formulations that allow us to exploit the locality
of the electronic structure within density-matrix-based theo-
ries. While this strongly reduces the computational scaling, for
example, for the computation of NMR chemical shifts within
density-functional theory from cubic to asymptotically linear,
the accuracy is numerically unchanged and fully con-
trolled.[5, 16]
As a medically relevant test system, we selected the
oxidoreductase tryparedoxin (Tpx), an essential enzyme of
Trypanosoma brucei, the parasite that causes African sleeping
sickness.[17] Tpx is inhibited by covalently binding to 2-
(chloromethyl)-5-(4-fluorophenyl)thieno[2,3-d]pyrimidine-4-
(3H)-one, CFT, which efficiently kills T. brucei.[18, 19] CFT
carries a 4-fluorophenyl moiety (Figure 1 A and Supporting
Information, Figure S5). The chlorine leaving group facili-
tates the covalent interaction with Cys40 in the active site of
Tpx.
In the asymmetric unit of our monoclinic crystals, three
protein chains with two different inhibitor orientations are
present (PDB: 6GXY, binding pose 1 for chains A and B,
binding pose 2 for chain C, Figure 1B).[19] In binding pose 1,
the covalently bound CFT features extensive intramolecular
interactions with the protein, including T-shaped p-stacking
interactions with Trp70 and a weak hydrogen bond of the CFT
fluorine with the backbone-Ha of Glu107. In binding pose 2,
CFT is not in contact with the protein beyond the covalent
bond to Cys40, and its fluorine atom is solvent exposed
instead. In both, crystal and solution, CFT binding to the wild-
type protein in pose 1 leads to Tpx dimerization mediated by
extensive intermolecular inhibitor–inhibitor stacking and
inhibitor–protein interactions.[19] The dissociation constant
for the CFT-induced Tpx dimer is approximately 5 mm. In
binding pose 2, dimerization is structurally not possible. We
Figure 1. Interaction of T. brucei oxidoreductase tryparedoxin (Tpx) with a covalent inhibitor. A) cysteine-reactive CFT (top) and non-reactive MFT
(bottom). B) Overlay of Tpx–CFT monomers in poses 1 and 2 as observed in our crystal structures (PDB: 6GXY).[19] C–F) Depiction of the QM
region and MM embedding. Tpx is shown in white, water in blue, and all atoms in the QM region as orange sticks. The inhibitor is highlighted in
red with its fluorine atom as green sphere. C) shows the Tpx–CFT dimer, D) the inhibitor in solution, E) the Tpx–CFT monomer in pose 1, and
F) the Tpx–CFT monomer in pose 2.
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identified residue Trp39 to be crucial for dimerization.
Mutation of this active-site residue to alanine (Tpx-W39A)
yields a protein that can still covalently interact with CFT, but
dimerization upon inhibitor binding is extremely weak
(Supporting Information, Figure S1).[19]
The 19F signals for free CFT and its unreactive analogue 2-
methyl-5-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4(3H)-one,
MFT, which is missing the chlorine leaving group (Fig-
ure 1A), were measured in solution at 298 K. Both 19F
chemical shifts were found to be very similar (114.79 and
114.77 ppm, respectively). Upon binding of CFT to Tpx and
the subsequent dimerization, a downfield chemical shift of
approximately 0.3 ppm for the 19F signal (114.47 ppm) and
substantial line broadening are observed, in agreement with
incorporation of CFT into a high molecular weight, dimeric
complex (Figure 2). Hence, the simultaneous availability of
19F NMR and X-ray data for the Tpx–inhibitor system renders
it exceptionally well-suited for systematic 19F chemical shift
studies. At high concentrations (greater than 500 mm), the 19F
chemical shift for the CFT–Tpx complex does not depend on
the concentration of the protein–inhibitor complex. This
suggests that under these conditions the 19F chemical shift is
not influenced by the monomer/dimer equilibrium since these
concentrations are far above the KD for dimerization. Only
after significantly lowering the concentration, the 19F signal
starts to shift further downfield, indicating an increasing
population of the monomer in exchange with the dimer
(Supporting Information, Figure S2). However, due to limi-
tations in the signal-to-noise ratio for the 19F NMR measure-
ments at high dilution, the concentration of the complex could
not be reduced far enough below the KD (! 5 mm) to reach
conditions where the monomer is exclusively observed. In
agreement with the above observation, the measured chem-
ical shift for CFT bound to the W39A-mutant is shifted
further downfield by an additional approximately 0.8 ppm
compared to the WT complex (113.7 ppm). This mutant
does not significantly dimerize, and the distances from the
inhibitors fluorine group to the W39 Ca atom and to the W39
indole group are more than 16  and 11.5 , respectively, and
thus should not affect the inhibitors 19F chemical shift. Ergo,
this mutant can be used as a reference point for the 19F
chemical shift of CFT bound to a Tpx monomer.
In contrast to small organic molecules, the free energy
landscape of solvated biomolecules typically does not possess
one deep minimum, but rather a multitude of energetically
close configurations that are thermodynamically accessible at
physiological temperatures. In the NMR experiment, this
implies the recording of an ensemble-averaged NMR chem-
ical shift. Therefore, many different configurations of the
system have to be taken into account to compute the observed
chemical shift.[20] It has been demonstrated that inclusion of
bond-length and bond-angle vibrations is often crucial for
reliable chemical-shift computations.[21, 22] Furthermore, the
different relative orientations of molecules have to be
accounted for as well. Here, we present a robust methodology
based on MM-MD sampling and subsequent QM/MM
calculations of 19F NMR chemical shifts to identify CFTs
binding poses relevant in solution.
Based on the crystal structure of the Tpx–CFT complex
(PDB: 6GXY),[19] we computed separate MM-MD trajecto-
ries for free CFT and MFT in solution, for the monomeric
complex with CFT bound in either pose 1 or 2, and the Tpx-
dimer with both protomers binding to CFT in pose 1 (see the
Supporting Information for setup details). An analysis of the
complex stability during the simulations and inhibitor flexi-
bility is given in Figures S4–S8 and Table S2 in the Supporting
Information.
Subsequently, the 19F chemical shifts of the inhibitor were
calculated with our linear-scaling methods[5, 16] for 200 snap-
shots taken evenly spaced in time from each MD trajectory.
All interactions of either the protein or solvent atoms with the
inhibitor were included explicitly. The aim was to perform
high quality 19F chemical-shift calculations on a large scale,
based on an adequate description of the accessible phase
space. The configurational ensembles included, for example,
different solvation patterns or orientations of the inhibitor
towards Tpx.
The high electron density of 19F renders its spectroscopic
properties, such as NMR chemical shifts, particularly chal-
lenging to calculate.[23] Motivated by previous studies,[12, 13] we
tested KT2[24] and B97-2[25] together with the NMR-specific
basis set pcS-1,[26] and the necessary QM buffer size (Support-
ing Information, Figure S9). Both functionals show identical
QM size convergence. As the radius of the QM region is
increased from 4 to 5 , the calculated chemical shift changes
by more than 0.5 ppm, highlighting the importance of
Figure 2. Comparison of experimentally measured (A) and calculated
(B) 19F NMR shifts. A) We compare CFT and MFT in solution, CFT in
the dimeric complex and the W39A monomeric mutant. In the experi-
ment, only one peak could be found for the monomeric protein.
B) The computed averages are shown as vertical lines with the SEM
indicated by an area shaded with decreased saturation. The calcula-
tions distinguish between two poses observed in the crystal structure
(Figure 1). Importantly, the calculations and the experiment reveal the
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a sufficiently large QM sphere. A 7  QM buffer region
around the inhibitor was found to be necessary to obtain size-
converged shifts. Hence, we performed QM/MM-NMR
calculations with KT2/pcS-1 for a 7  QM region. For the
dimeric wild-type Tpx–CFT complex, this region (Figure 1C)
includes more than 1000 atoms. In combination with the
200 sampling points taken from each of the individual MD
trajectories, this makes it one of the largest QM-based
19F NMR chemical-shift calculations reported so far.[7,8, 27]
The QM size and the combined number of calculations in
this context are unprecedented and are at the frontier of what
is currently possible for such large biological systems. The
embedded QM regions are shown in Figure 1C–F. A detailed
description is given in the Supporting Information (Support-
ing Information, Table S3).
It is important to note that the values of the calculated 19F
shifts for individual MD frames are scattered over a large shift
range of about 60 ppm (Supporting Information, Figure S10).
This is, however, not unexpected due to bond-length and
bond-angle vibrations in the MD simulations.[21] The vibra-
tions causing these distributions, especially those of the C–F
bond, are fast processes on the spectroscopic time scale, and
thus are not observed experimentally. We use the experimen-
tally measured 19F signal of free CFT in solution as reference
for our calculated values, as relative shieldings are much more
accurate.
As expected, our calculated 19F chemical shifts correctly
predict that the chemical shifts for free CFTand MFTare very
similar to each other. Importantly, the predicted chemical
shift for the inhibitor bound to Tpx is calculated to be
downfield shifted compared to free CFT. An even more
pronounced downfield shift compared to free CFT is pre-
dicted for CFT bound to monomeric Tpx in binding pose 1.
This is in excellent agreement with what is observed
experimentally for CFT bound to the monomeric W39A
Tpx-mutant and in our dilution experiments (Supporting
Information, Figures S1 and S2). In contrast, for the mono-
meric complex in pose 2, a chemical shift is calculated that lies
between free CFT and the dimeric complex. Thus, our
calculations qualitatively predict the correct order of the 19F
chemical shifts for CFT in the different states, as well as the
true direction of chemical-shift changes induced by protein
binding and complex dissociation. They further suggest that
binding pose 2 of CFT observed in chain C of the crystal
structure is not relevant in solution, as one would then expect,
for CFT bound to the monomeric W39A mutant, a 19F signal
with a chemical shift in between those of free CFT and CFT
bound to dimeric wild-type Tpx. This agrees well with the
extended degree of solvent exposure of the inhibitor in this
binding pose (Supporting Information, Figure S8), thus
rendering it more similar to the free inhibitor. However, our
calculations overestimate the chemical-shift differences
between the different states. Already the calculated chemical
shift difference between free CFT and free MFT (0.58 ppm) is
larger than the measured one (0.02 ppm). This pattern
continues for the other pairwise chemical-shift differences
(CFT vs. CFT–WT: 0.32 ppm/2.48 ppm; Dimer vs. Monomer
(pose 1): 0.77 ppm/0.97 ppm). Nevertheless, the computed
trend allows us to discriminate between the different struc-
tures observed experimentally and to assign the measured
shifts to a given conformer.
The accuracy of the prediction could be further increased
by using a higher level of theory, a larger basis set, or more
accurate dynamics (QM/MM-MD instead of MM-MD)
improving the description of bond lengths, vibrations, and
non-covalent interactions, which would entail, however,
significantly higher computational costs.
Our study underlines the usefulness of 19F NMR for the
investigation of complex protein–inhibitor interactions, show-
cases current computational possibilities, and illustrates the
power of predicting 19F NMR chemical shifts in a complex
biological system as a prerogative for further biomedical
applications and drug design.
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